Compare AT&T Inc. (T) vs TG Therapeutics Inc (TGTX) Price & Performance

AT&T (T) trades at $25.61, down 0.21% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with a P/E of 8.45, net income margin of 16.94%, and consistent earnings beats in recent quarters. Recent developments include strategic partnerships with Amazon for satellite broadband and continued fiber expansion, positioning the company for growth in the competitive telecom sector.

The outlook for AT&T remains positive with analyst consensus pointing to 8% upside to the $27.69 price target. Key opportunities include fiber infrastructure expansion and wireless network enhancements, while risks involve heavy capital expenditures and competitive pressures. The stock offers value with attractive valuation metrics and dividend yield, supported by improving cash flow trends and debt reduction efforts.

TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.

The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.